Marksans Pharma Limited (NSE:MARKSANS)
302.90
-8.10 (-2.60%)
Oct 19, 2026, 3:30 PM IST
Marksans Pharma Revenue
Marksans Pharma had revenue of 8.41B INR in the quarter ending June 30, 2026, with 35.61% growth. This brings the company's total for the last twelve months to 31.72B, up 19.59% year-over-year. In the fiscal year ending March 31, 2026, Marksans Pharma had annual revenue of 29.51B with 12.51% growth. That makes Marksans Pharma the 13,751st largest company in the world by revenue and 666th in India.
Revenue (ttm)
31.72B
Revenue Growth
+19.59%
P/S Ratio
4.33
Revenue / Employee
18.82M
Employees
1,685
Market Cap
137.33B
Revenue by Geography
- United States and North America 15.33B 52.0%
- Europe and The United Kingdom 10.15B 34.4%
- Australia and New Zealand 3.03B 10.3%
- Rest of World 994.34M 3.4%
Fiscal year ended Mar 31, 2026 See the full Marksans Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 29.51B | 3.28B | 12.51% |
| Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Divi's Laboratories | 112.30B |
| Lenskart Solutions | 96.34B |
| Laurus Labs | 72.70B |
| Indegene | 38.13B |
| NATCO Pharma | 34.85B |
| Dr. Agarwal's Health Care | 22.07B |
| Rainbow Children's Medicare | 18.20B |
Marksans Pharma News
- 2 months ago - Marksans Pharma Transcript: Q1 26/27 - Transcripts
- 2 months ago - Marksans Pharma Quarterly report: Q1 2027 - Filings
- 2 months ago - Marksans Pharma Slides: Q1 2027 - Filings
- 3 months ago - Marksans Pharma to acquire ABCnow GmbH for €892,384 - Business Upturn
- 3 months ago - Marksans Pharma announces ₹0.90 per share final dividend for FY26 - Business Upturn
- 3 months ago - Marksans Pharma announces 90% final dividend ahead of AGM - Business Upturn
- 3 months ago - Marksans Pharma submits machine-readable financial results for March 2026 - Business Upturn
- 3 months ago - Marksans Pharma launches campaign to prevent transfer of unclaimed dividends - Business Upturn